Introduction
============

Ankylosing spondylitis (AS) is the prototypic and debilitating type of spondyloarthritis, which is an autoimmune disorder ([@b1-ijmm-43-03-1179]). AS often affects the axial joints, including the sacroiliac joint and spine, and induces new bone formation and ultimately ankylosis ([@b2-ijmm-43-03-1179],[@b3-ijmm-43-03-1179]).

AS is associated with the interplay of genetic risks and environmental triggers, and its etiology and pathogenesis remain largely unknown. A number of studies have reported a strong association between the major histocompatibility complex class I allele human leukocyte antigen B27 (HLA-B27) and AS ([@b4-ijmm-43-03-1179]-[@b6-ijmm-43-03-1179]). However, the mechanism by which HLA-B27 causes a predisposition to AS remains unclear. T cells and a number of immune pathways, including the interleukin (IL)-17/IL-23 pathway and control of nuclear factor-κB (NF-κB) activation, have been reported to be closely associated with AS ([@b5-ijmm-43-03-1179],[@b6-ijmm-43-03-1179]). Currently, it is difficult to diagnose AS during the early stages due to the lack of accurate diagnostic biomarkers.

Long non-coding RNA (lncRNA) is a type of non-protein-coding transcript with a length of \>200 nucleotides; they are emerging as key regulators in various biological processes ([@b7-ijmm-43-03-1179]). Recent studies have indicated that lncRNAs, including lncRNA-AK001085, lnc-zinc finger protein 354A (ZNF354A)-1, lnc-Lin-54 DREAM MuvB core complex component (LIN54)-1, lnc-Facioscapulohumeral muscular dystrophy region gene 2 family member C (FRG2C)-3 and lnc-ubiquitin specific peptidase 50 (USP50)-2, serve roles in AS ([@b8-ijmm-43-03-1179],[@b9-ijmm-43-03-1179]). Some researchers have also revealed that mRNAs, such as programmed cell death 1 (PDCD1) ([@b1-ijmm-43-03-1179]), caspase recruitment domain-containing protein 11 (CARD11) ([@b10-ijmm-43-03-1179]), phospholipase Cγ1 (PLCG1) ([@b11-ijmm-43-03-1179],[@b12-ijmm-43-03-1179]) and DNA methyltransferase 1 (DNMT1) ([@b13-ijmm-43-03-1179]), may be involved in the pathogenesis of AS.

In the present study, the key differentially expressed (DE) mRNAs (DEmRNAs) and DElncRNAs in AS were identified using RNA sequencing and bioinformatics analysis. DElncRNA-DEmRNA co-expression network construction, identification of nearby target DEmRNAs of DElncRNAs and functional annotation of DEmRNAs were performed in order to understand the biological functions of the key DEmRNAs and DElncRNAs in AS.

Materials and methods
=====================

Patients and samples
--------------------

Three patients with AS and three normal controls were enrolled in the present study from 2nd Affiliated Hospital, School of Medicine, Zhejiang University (Zhejiang, China). The patients with AS were aged 37, 36 and 40 years old, and all were HLA-B27^+^ and male. These patients were diagnosed with AS based on kyphotic deformity, bilateral damage of the sacroiliac joint observed in the computed tomography results, and spinal fusion and sacroiliac arthrodesis observed in the X-ray results. All of the patients had not received treatment with non-steroidal anti-inflammatory drugs or biologics and they had not exhibited complications. The normal controls were aged 35, 36 and 37 years old and were male. None of the six participants had any other type of autoimmune disease. Blood samples were obtained from all six participants. All of the participants submitted written informed consent and the present study was approved by the Ethics Committee of 2nd Affiliated Hospital, School of Medicine, Zhejiang University.

Library preparation and high-throughput sequencing
--------------------------------------------------

Total RNA was isolated from the blood samples with TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer\'s instructions. A NanoDrop ND-2000 spectrophotometer (Thermo Fisher Scientific, Inc.) was used to check the concentration and purity of the RNA. The integrity of the RNA was confirmed using 2% agarose gel and the RNA integrity number (RIN) was obtained using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies, Inc., Santa Clara, CA, USA). The thresholds of total RNA for cDNA library construction were as follows: i) Amount of RNA, \>5 *μ*g; ii) concentration of RNA; ≥200 ng/ml; iii) 1.8\<optical density (OD)~260/280~\<2.2; iv) 2.0\<OD~260/280~; and v) RIN value, \>8.0.

Firstly, the ribosomal RNA was removed from the total RNA using a Ribo-Zero Magnetic kit (Epicentre; Illumina, Inc., San Diego, CA, USA). In addition, \'Soap\' software (version 1.03; [soap.genomics.org.cn/SOAPdenovo-Trans.html\#intro2](http://soap.genomics.org.cn/SOAPdenovo-Trans.html#intro2)) was used to compare the reads of the rRNA, and then to write a perl script to remove it from the FastQ file. Subsequently, the cDNA library for RNA sequencing was contrasted using the TruSeq RNA Sample Prep kit (Illumina, Inc.). Briefly, the retrieved RNA was fragmented by adding First Strand Master Mix and then first-strand cDNA was generated using the First Strand Master mix and Super Script II reverse transcription (Invitrogen; Thermo Fisher Scientific, Inc.) with the following reaction conditions: 25°C for 10 min, 42°C for 50 min and 70°C for 15 min. Following purification of the product with Agencourt RNA Clean XP beads (Beckman Coulter, Inc., Brea, CA, USA), Second Strand Master mix and dATP, dGTP, dCTP and dUTP mix (Beckman Coulter, Inc.) were added to synthesize the second-strand cDNA (16°C for 1 h). Subsequently, the purified cDNA was combined with End Repair Mix (Thermo Fisher Scientific, Inc.) and incubated at 30°C for 30 min. Following purification with beads (Qiagen, Inc., Valencia, CA, USA), A-Tailing mix (Qiagen, Inc.) was added into the reaction system, which was incubated at 37°C for 30 min. Adenylate 3\' Ends DNA, Index Adapter and Ligation mix (Qiagen, Inc.) were combined and incubated at 30°C for 10 min. Subsequently, the Uracil-N-Glycosylase enzyme was added into the purified ligation product and incubated at 37°C for 10 min. A total of 15 rounds of polymerase chain reaction (PCR) amplification were conducted with PCR Primer Cocktail (Illumina, Inc.) and PCR Master Mix (Illumina, Inc.) to enrich the cDNA fragments. The PCR products were then purified with AMPure XP beads (Qiagen, Inc.). The qualified libraries were amplified on cBot (Illumina, Inc.) to generate a cluster on the flow cell (TruSeq PE Cluster kit v3-cBot-HS; Illumina, Inc.). The amplified flow cell was sequenced on an Illumina HiSeq X Ten platform (Illumina, Inc.).

Quality control of raw sequence
-------------------------------

Quality control of the raw reads derived from the RNA sequencing was performed to obtain clean reads of high quality. Briefly, quality control involved trimming low-quality reads, including adaptor sequences, sequences with a quality score \<20 and sequences with an N-base rate of raw reads \>10%, using SeqPrep (version 1.2; [github.com/jstjohn/SeqPrep](http://github.com/jstjohn/SeqPrep)) and Sickle (version V3.4.0; [github.com/najoshi/sickle](http://github.com/najoshi/sickle)).

Clean reads mapping
-------------------

Sequences were aligned to the human reference genome GRCh38.p7 (Ensembl v84; [www.ensembl.org/index.html](http://www.ensembl.org/index.html)) using hierarchical indexing for the spliced alignment of the transcripts programme HISAT2 (version 2.1.0; [ccb.jhu.edu/software/hisat2/index.shtml](http://ccb.jhu.edu/software/hisat2/index.shtml)). Then, StringTie (version v1.3.4; [ccb.jhu.edu/software/stringtie/](http://ccb.jhu.edu/software/stringtie/)) was used to assemble and quantify the transcripts in each sample. Ultimately, differential gene expression analysis was performed with Ballgown (version 3.7; [www.bioconductor.org/packages/release/bioc/html/ballgown.html](http://www.bioconductor.org/packages/release/bioc/html/ballgown.html)) in R environment.

Identification of DEmRNAs and DElncRNAs
---------------------------------------

Using Ballgown, the DEmRNAs and DElncRNAs between the patients with AS and normal controls were identified with P\<0.05. The false discovering rate (FDR)-adjusted P-value of the test statistic was used. Hierarchical clustering of the DElncRNAs and DEmRNAs expression profile was performed using hcluster in R language (version 3.3.3; stat.ethz.ch/R-manual/R-devel/library/stats/html/hclust.html).

AS-specific protein-protein interaction (PPI) network construction
------------------------------------------------------------------

PPI networks of the top 30 up- and down-regulated DEmRNAs, respectively, were constructed using BioGRID (version 3.5; [thebiogrid.org](http://thebiogrid.org)).

AS-specific weighted DEmRNA-DElncRNA co-expression network analyses
-------------------------------------------------------------------

Weighted Gene Co-expression Network Analysis (WGCNA_1.64-1; [horvath.genetics.ucla.edu/html/CoexpressionNetwork/Rpackages/WGCNA/](http://horvath.genetics.ucla.edu/html/CoexpressionNetwork/Rpackages/WGCNA/)) ([@b14-ijmm-43-03-1179]) is an R package for weighted correlation network analysis, which is also known as weighted gene co-expression network analysis. Using WGCNA, AS-specific weighted DEmRNA-DElncRNA co-expression network analysis was performed. The pairwise Pearson\'s correlation coefficients (PCCs) between the DElncRNAs and DEmRNAs in patients with AS were calculated. DElncRNA-DEmRNA pairs with \|PCC value ≥0.90\| and P\<0.001 were used to construct an AS-specific weighted DEmRNA-DElncRNA co-expression network, which was deciphered using the online-based software GeneCodis3 (genecodis.cnb.csic.es/analysis).

Functional analyses of DEmRNAs co-expressed with DElncRNAs in AS
----------------------------------------------------------------

The DEmRNAs of these DElncRNA-DEmRNA pairs with \|PCC value ≥0.90\| and P\<0.001 were used to conduct Gene Ontology (GO; [www.geneontology.org/](http://www.geneontology.org/)) and Kyoto Encyclopedia of Genes and Genomes (KEGG; [www.genome.jp/kegg/](http://www.genome.jp/kegg/)) molecular pathway enrichment analysis using GeneCoDis3.

DEmRNAs close to DElncRNAs with cis-regulatory effects
------------------------------------------------------

Previous studies have reported that lncRNAs can regulate genes that are transcribed near to them, consistent with activity in cis-regulatory elements ([@b15-ijmm-43-03-1179],[@b16-ijmm-43-03-1179]). Therefore, in the present study DEmRNAs that were close cis targets of DElncRNAs were identified by searching for DEmRNAs that were transcribed within a 100-kb window up- or downstream of DElncRNAs between the patients with AS and the normal controls ([@b17-ijmm-43-03-1179]).

Validation of the expression of DEmRNAs and DElncRNAs using the GSE73754 and GSE25101 datasets
----------------------------------------------------------------------------------------------

The mRNA expression profile of 52 patients with AS and 20 normal controls (Canadian cohort) in the GSE73754 dataset (GPL10558 Illumina HumanHT-12 V4.0 expression beadchip), which was downloaded from the Gene Expression Omnibus (GEO; [www.ncbi.nlm.nih.gov/gds](http://www.ncbi.nlm.nih.gov/gds)). The mRNA and lncRNA expression profile of 16 patients with AS and 16 normal controls (Australian cohort) in the GSE25101 dataset (GPL6947 Illumina HumanHT-12 V3.0 expression beadchip) was also downloaded from the GEO database. The expression levels of the selected DEmRNAs and DElncRNAs between the patients with AS and normal controls in the present study were validated using the GSE73754 and GSE25101 datasets, and the difference in the expression levels was visualized using box plots.

Receiver operating characteristic (ROC) analyses
------------------------------------------------

To assess the diagnostic value of the DEmRNAs in AS, ROC analyses were conducted using pROC package (version 1.13.0) in R language ([cran.r-project.org/web/packages/pROC/index.html](http://cran.r-project.org/web/packages/pROC/index.html)). The area under the curve (AUC) under the binomial exact confidence interval was calculated. ROC curves were then generated.

Statistical analysis
--------------------

Values are displayed as the mean ± standard deviation. Student\'s t-test was used to assess differences among the groups, and P≤0.05 was considered to indicate a statistically significant difference. Co-expression associations between the lncRNAs and the protein-coding genes were estimated using pairwise PCC analysis using R language (version 3.3.3; stat. ethz.ch/R-manual/R-devel/library/stats/html/hclust.html).

Results
=======

Identification of DEmRNAs and DElncRNAs between patients with AS and normal controls
------------------------------------------------------------------------------------

Compared with the normal controls, 1,072 DEmRNAs (320 upregulated and 752 down-regulated) and 372 DElncRNAs (230 upregulated and 142 downregulated) in patients with AS were identified. The top 10 up- and downregulated DEmRNAs and DElncRNAs between the patients with AS and normal controls are shown in [Tables I](#tI-ijmm-43-03-1179){ref-type="table"} and [II](#tII-ijmm-43-03-1179){ref-type="table"}, respectively.

MANSC domain containing 1 (MANSC1) and DNMT1 were the most significantly up- and downregulated DEmRNAs between the patients with AS and normal controls, respectively (data not shown). NOTCH1 associated lncRNA in T-cell acute lymphoblastic leukemia 1 (NALT1) and RP11-837J7.4 were the most significantly up- and downregulated DElncRNAs between the patients with AS and normal controls, respectively (data not shown).

AS-specific PPI network construction
------------------------------------

The AS-specific PPI network consisted of 159 nodes and 164 edges. The top 10 mRNAs that had the highest degrees were Myc proto-oncogene basic helix-loop-helix transcription factor (MYC; degree=65), heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1; degree= 40), spectrin-a non-erythrocytic 1 (SPTAN1; degree=18), TATA-box binding protein associated factor 10 (TAF10; degree=9), ETS proto-oncogene 1 transcription factor (degree=7), NCK adaptor protein 1 (degree=6), eukaryotic translation initiation factor 4B (degree=5), KIAA1033 (degree=5), extended synaptotagmin 1 (degree=5) and tumor protein 53 (degree=5); of these, MYC, HNRNPA1, SPTAN1 and TAF10 were hub proteins of the AS-specific PPI network ([Fig. 1](#f1-ijmm-43-03-1179){ref-type="fig"}).

AS-specific weighted DEmRNA-DElncRNA co-expression network analysis
-------------------------------------------------------------------

A total of 3,505 lncRNA-mRNA pairs were identified, which included 302 DElncRNAs and 602 DEmRNAs with \|PCC value ≥0.90\| and P\<0.001. Based on these lncRNA-mRNA pairs, the negatively and positively co-expressed DEmRNA-DElncRNA interaction networks were constructed, respectively. The top 100 co-expressed DEmRNA-DElncRNA interaction network is presented in [Table III](#tIII-ijmm-43-03-1179){ref-type="table"}. Based on the positively co-expressed DEmRNA-DElncRNA interaction network, MSTRG.8559 (degree=226) and long intergenic non-protein coding RNA 987 (LINC00987; degree=209) were the top 2 DElncRNAs that were co-expressed with the greatest number of DEmRNAs ([Fig. 2](#f2-ijmm-43-03-1179){ref-type="fig"}). The selected co-expression DEmRNA-DElncRNA interaction network is presented in [Fig. 2](#f2-ijmm-43-03-1179){ref-type="fig"}.

Functional analysis of DEmRNAs co-expressing DElncRNAs between patients with AS and normal controls
---------------------------------------------------------------------------------------------------

Based on the GO enrichment analysis ([Fig. 3](#f3-ijmm-43-03-1179){ref-type="fig"}) of the 602 DEmRNAs that were co-expressed with DElncRNAs in patients with AS and normal controls, the significantly enriched GO terms were as follows: \'DNA repair\' (FDR=3.94×10^−4^; [Fig. 3A](#f3-ijmm-43-03-1179){ref-type="fig"}), \'carbohydrate metabolic process\' (FDR=5.66×10^−4^; [Fig. 3A](#f3-ijmm-43-03-1179){ref-type="fig"}), \'nucleus\' (FDR=3.34×10^−30^; [Fig. 3B](#f3-ijmm-43-03-1179){ref-type="fig"}) and \'protein binding\' (FDR=7.54×10^−31^; [Fig. 3C](#f3-ijmm-43-03-1179){ref-type="fig"}). \'T-cell receptor signaling pathway\' (FDR=2.29×10^−3^; [Fig. 4](#f4-ijmm-43-03-1179){ref-type="fig"}) and \'cell cycle\' (FDR=1.52×10^−3^; [Fig. 4](#f4-ijmm-43-03-1179){ref-type="fig"}) were the significantly enriched KEGG pathways.

DEmRNAs close to DElncRNAs with cis-regulatory effects
------------------------------------------------------

A total of 84 DElncRNAs and nearby cis target DEmRNA pairs, which included 73 DElncRNAs and 82 DEmRNAs, were obtained ([Table IV](#tIV-ijmm-43-03-1179){ref-type="table"}).

Validation of the expression of DEmRNAs and DElncRNAs using the GSE73754 and GSE25101 datasets
----------------------------------------------------------------------------------------------

A total of 4 DEmRNAs (DNMT1, PDCD1, CARD11 and PLCG1) were selected to perform expression validation using the GSE73754 dataset ([Fig. 5](#f5-ijmm-43-03-1179){ref-type="fig"}). The expression of all four DElncRNAs was downregulated in patients with AS when compared with the normal controls, which was generally consistent with the RNA sequencing data (DNMT1, P\<0.05; CARD11, P\<0.05; PDCD1, P\>0.05; PLCG1, P\>0.05). Three lncRNAs (cat eye syndrome chromosome region candidate 7, hydatidiform mole associated and imprinted and KIAA0125) and seven DEmRNAs \[MANSC1, adenosine triphosphatase sarcoplasmic/endoplasmic reticulum Ca^2+^ transporting 2 (ATP2A2), myeloid zinc finger 1 (MZF1), PDCD1, DNMT1, CARD11 and PLCG1\] were selected to perform expression validation using the GSE25101 dataset ([Fig. 6](#f6-ijmm-43-03-1179){ref-type="fig"}). The expression of KIAA0125 (P\>0.05), MANSC1 (P\>0.05), ATP2A2 (P\>0.05), MZF1 (P\>0.05), PDCD1 (P\>0.05), DNMT1 (P\<0.0001), CARD11 (P\<0.05) and PLCG1 (P\>0.05) was generally consistent with the RNA sequencing data.

ROC curve analysis
------------------

ROC curve analyses and the AUC were used to assess the discriminatory ability of the four DEmRNAs (DNMT1, PDCD1, CARD11 and PLCG1) among the 52 patients with AS and 20 normal controls of the GSE73754 dataset. The AUCs of PDCD1 and PLCG1 were \<0.7 (data not shown). The AUCs of CARD11 and DNMT1 were 0.782 and 0.737, respectively ([Fig. 7](#f7-ijmm-43-03-1179){ref-type="fig"}). For AS diagnosis, the sensitivity (proportion of true positive) and 1-specificity (proportion of false positive) of CARD11 were 70.0 and 80.8%, respectively, and for DNMT1 were 75.0 and 69.2%, respectively ([Fig. 7](#f7-ijmm-43-03-1179){ref-type="fig"}).

Discussion
==========

AS is a type of autoimmune disorder that is associated with HLB-27 and T-cells; however, its etiology and pathogenesis remain unclear ([@b18-ijmm-43-03-1179]). The delays in the diagnosis of AS and the insufficient responses to the currently available therapeutics supports the requirement for a greater understanding of its pathogenesis.

A previous microarray study identified four lncRNAs, lnc-ZNF354A-1, lnc-LIN54-1, lnc-FRG2C-3 and lnc-USP50-2, that are involved in the abnormal osteogenic differentiation of mesenchymal stem cells (MSCs) in patients with AS. The expression of these four lncRNAs was positively correlated with that of bone morphogenetic protein 2 and Noggin in MSCs from healthy donors ([@b8-ijmm-43-03-1179]). A recent study reported that lncRNA-AK001085 was downregulated in patients with AS and served as a potential diagnostic indicator, thus, lncRNA-AK001085 was considered to be a potential suppressor of AS ([@b9-ijmm-43-03-1179]). Due to the lack of research, the regulatory mechanism of the majority of lncRNAs in AS remains unknown. In the present study, the key DEmRNAs and DElncRNAs associated with AS were identified and their functions in AS were investigated using RNA sequencing and bioinformatics analysis.

LINC00342 was demonstrated to be upregulated in patients with non-small cell lung cancer and its expression was positively correlated with lymph node metastasis and the Tumor-Node-Metastasis stage ([@b19-ijmm-43-03-1179]). Coiled-coil domain containing 26 (CCDC26) is also a tumor-associated lncRNA that regulates the growth of glioma, pancreatic cancer and myeloid leukemia cells ([@b20-ijmm-43-03-1179]-[@b22-ijmm-43-03-1179]). In the present study, LINC00342 and CCDC26 were downregulated in patients with AS, which suggests that they may serve roles in AS. Further studies are required in order to identify their precise function in AS.

Furthermore, the results of the present study indicated that many novel DElncRNAs may be involved in AS. In order to investigate their functions in AS, a weighted DElncRNA-DEmRNA co-expression network was constructed and functional annotation of the DElncRNAs co-expressed with DElncRNAs was performed. A total of 3,505 DElncRNA-DEmRNA co-expression pairs, which included 302 DElncRNAs and 602 DEmRNAs, were obtained. Based on the DEmRNAs co-expressed with DElncRNAs, \'T-cell receptor signaling pathway\' was a significantly enriched pathway. T-cells have been demonstrated by previous studies to serve important roles in the pathology of AS ([@b23-ijmm-43-03-1179]-[@b25-ijmm-43-03-1179]). HLA-B27-reactive cluster of differentiation-4^+^ T-cells have been reported to be involved in the pathogenesis of spondyloarthropathies ([@b26-ijmm-43-03-1179]). The number of peripheral T-helper (Th)-2 and Th17 lymphocytes has been demonstrated to be increased in AS, which is suggestive of their potential roles in AS ([@b27-ijmm-43-03-1179],[@b28-ijmm-43-03-1179]). Therefore, the results of the present study support those of previous studies as well as the importance of the T-cell receptor signaling pathway in AS. Furthermore, the DEmRNAs that were enriched in the T-cell receptor signaling pathway, including NF-κB inhibitor β, CARD11, P21 (Ras-related C3 botulinum toxin substrate 1) activated kinase 6, protein kinase Cθ, PLCG1, PDCD1, FYN proto-oncogene Src family tyrosine kinase, protein kinase B2 and Vav guanine nucleotide exchange factor 3, may be involved with AS by regulating the T-cell receptor signaling pathway.

Among these DEmRNAs, PDCD1 is a known AS-associated gene. PDCD1 is a member of the immunoglobulin superfamily that is expressed on the surface of peripheral T-cells, and regulates T-cell responses and the maintenance of peripheral tolerance ([@b29-ijmm-43-03-1179],[@b30-ijmm-43-03-1179]). A previous study demonstrated that the expression levels of PDCD1 on activated T-cells were decreased in patients with AS ([@b1-ijmm-43-03-1179]). Downregulation of PDCD1 may be involved in AS by stimulating the activity of T-cells and elevating the production of cytokines, which promotes spinal inflammation and destruction in patients with AS ([@b1-ijmm-43-03-1179]). Downregulated PDCD1 was also identified in patients with AS in the present study, which provides evidence to support the results of the previous study.

CARD11 is a shared member of the CARD and CARD-containing membrane-associated guanylate kinase protein 1 families that has been reported to serve a vital role in regulation of inflammation and the immune response ([@b31-ijmm-43-03-1179]). Although to the best of our knowledge, there have been no studies that have reported on the association between CARD11 and AS, downregulated CARD11 has been implicated in another type of autoimmune disease, rheumatoid arthritis, via NF-κB activation, reduced Th17 responses and the decreased production of proinflammatory cytokines, including IL-1β, IL-6 and IL-17 ([@b10-ijmm-43-03-1179],[@b32-ijmm-43-03-1179],[@b33-ijmm-43-03-1179]). Joint inflammation and destruction were demonstrated to be attenuated by CARD11 small interfering RNA treatment in mice ([@b10-ijmm-43-03-1179]). Considering the crucial roles of NF-κB activation, Th17 cells and proinflammatory cytokines in AS, it was hypothesized that CARD11 may also be a key regulator of AS.

Similar to CARD11, PLCG1 has been reported to be associated with other types of autoimmune disease, including multiple sclerosis and lymphoproliferative syndrome ([@b11-ijmm-43-03-1179],[@b12-ijmm-43-03-1179]). Furthermore, the interaction between PLCG1 and linker for activation of T-cells (LAT) was revealed to be involved with the activation and proliferation of T-cells ([@b11-ijmm-43-03-1179],[@b12-ijmm-43-03-1179]). The production of IL-6 by T-cells is also regulated by PLCG1-LAT ([@b11-ijmm-43-03-1179],[@b12-ijmm-43-03-1179]). Therefore, downregulated PLCG1 in the patients with AS in the present study may serve important roles in the progression of AS by regulating T-cells and the production of IL-6.

DNMT1 encodes an enzyme that establishes and regulates patterns of methylated cytosine residues ([@b13-ijmm-43-03-1179]). A previous study observed downregulated and hypermethylated DNMT1 in the peripheral blood mononuclear cells of patients with AS when compared with normal controls, which suggests that DNMT1 may be a potential biomarker of AS ([@b13-ijmm-43-03-1179]). Thus, the downregulation of DNMT1 observed in patients with AS in the present study is consistent with this previous study.

Based on the ROC analysis in the present study, CARD11 and DNMT1 may have great diagnostic value for AS, and therefore may be potential biomarkers.

LINC00987 was a downregulated lncRNA in the patients with AS in the present study, and was co-expressed with DNMT1, CARD11 and PLCG1. In addition, DNMT1 and PLCG1 were co-expressed with another downregulated lncRNA, MSTRG.8559, in the patients with AS. Furthermore, LINC00987 and MSTRG.8559 were two hub lncRNAs of the positively co-expressed DElncRNA-DEmRNA network, which regulates the majority of the DEmRNAs in AS. It was hypoth-esized that these two DElncRNAs may serve crucial roles by regulating the expression of DNMT1, the T-cell receptor signaling pathway and its associated genes. Further studies are required to further investigate the biological functions of LINC00987 and MSTRG.8559, particularly those in AS.

RP11-837J7.4 and NALT1 were the most significantly down- and upregulated, respectively, DElncRNAs in patients with AS in the present study; however, their biological functions remain known. Further studies are required in order to identify whether these two DElncRNAs could serve as diagnostic biomarkers for AS.

Previous studies have revealed the prevalence of lncRNA-mediated cis regulation on nearby transcription ([@b34-ijmm-43-03-1179]-[@b36-ijmm-43-03-1179]). The 84 AS-specific DElncRNA and nearby cis target DEmRNA pairs obtained in the present study provide novel information for understanding the biological functions of lncRNAs in AS.

In conclusion, the present study obtained lncRNA and mRNA expression profiles from patients with AS and normal controls using RNA sequencing. A number of key genes, including PDCD1, DNMT1, CARD11 and PLCG1, that are involved in AS were identified. In addition, the results indicated that numerous novel DElncRNAs may be involved in AS. Furthermore, the functions of DElncRNAs in AS were investigated using functional annotation of DEmRNAs co-expressed with DElncRNAs and through the identification of nearby target DEmRNAs of DElncRNAs. These results may support further studies on the potential roles of lncRNAs in AS. However, the sample size for RNA-seq was small, which is a limitation of the present study, therefore, studies with larger sample sizes are required in order to confirm this conclusion.
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![Validation the expression of selected DEmRNAs between patients with AS and normal controls in the GSE73754 dataset. The x-axis presents the AS and normal control groups and the y-axis presents the expression levels of (A) CARD11, (B) DNMT1, (C) PDCD1 and (D) PLCG1. Data are presented as the median and the 75th and 25th percentiles. ^\*^P\<0.05 vs. control. AS, ankylosing spondylitis; DEmRNA, differentially expressed mRNA; CARD11, caspase recruitment domain-containing protein 11; DNMT1, DNA methyltransferase 1; PDCD1, programmed cell death 1; PLCG1, phospholipase Cγ1.](IJMM-43-03-1179-g04){#f5-ijmm-43-03-1179}

![Validation of the expression of selected DEmRNAs and DElncRNAs between patients with AS and the normal controls in the GSE25101 dataset. The x-axis presents the AS and normal control groups and the y-axis presents the expression levels. (A) The selected DEmRNAs and (B) The selected DElncRNAs. AS, ankylosing spondylitis; DEmRNA, differentially expressed mRNA; DElncRNA, differentially expressed long non-coding RNA; CARD11, caspase recruitment domain-containing protein 11; DNMT1, DNA methyltransferase 1; PDCD1, programmed cell death 1; PLCG1, phospholipase Cγ1; MANSC1, MANSC domain containing 1; ATP2A2, adenosine triphosphatase sarcoplasmic/endoplasmic reticulum Ca^2+^ transporting 2; MZF1, myeloid zinc finger 1; CECR7, cat eye syndrome chromosome region candidate 7; HYMAI, hydatidiform mole associated and imprinted.](IJMM-43-03-1179-g05){#f6-ijmm-43-03-1179}

![ROC curves of CARD11 and DNMT1 comparing patients with ankylosing spondylitis and normal controls in the GSE73754 dataset. ROC curves displayed the diagnostic ability of differentially expressed long non-coding RNA with sensitivity (the proportion of true positive) and 1-Specificity (the proportion of false positive). The x-axis presents 1-specificity and y-axis presents sensitivity. (A) CARD11 and (B) DNMT1. ROC, receiver operating characteristic; CARD11, caspase recruitment domain-containing protein 11; DNMT1, DNA methyltransferase 1; AUC, area under the curve.](IJMM-43-03-1179-g06){#f7-ijmm-43-03-1179}

###### 

Top 10 up- and downregulated DEmRNAs between ankylosing spondylitis and normal controls.

  DEmRNAs   log2.Fold change   P-value       SD_fpkm_C     SD_fpkm_T     Regulation
  --------- ------------------ ------------- ------------- ------------- ------------
  IGHG1     −2.021979095       0.047255959   8.80361236    0.515381703   Down
  IGHG4     −1.859252007       0.025210597   3.368882506   0.227307135   Down
  TRAJ18    −1.643179443       0.035866398   10.07677638   4.09159482    Down
  TRAJ11    −1.524711275       0.014505975   8.654159887   4.620202967   Down
  TRAJ5     −1.49467071        0.000440647   6.737567008   2.426348758   Down
  TRAJ44    −1.46271809        0.001143618   4.42364856    1.848651282   Down
  ETS1      −1.335519855       0.031765089   32.5763664    9.312805914   Down
  LAIR2     −1.302776176       0.044790098   0.834353066   1.050550336   Down
  ESYT1     −1.259200819       0.002673524   15.14634661   6.658023234   Down
  NCR3      −1.247053856       0.033379705   5.641796936   2.719067002   Down
  CLC       1.194865831        0.043003696   21.60725157   83.0330712    Up
  S100A12   0.98788469         0.00518168    40.98384277   110.0364144   Up
  CMPK2     0.904925259        0.01474919    0.622597776   2.021786682   Up
  ZFP36     0.842014426        0.012071156   6.481954564   7.910723637   Up
  MME       0.746984037        0.031312145   9.013396028   20.24882244   Up
  LIN7A     0.711395439        0.049387957   3.456739121   4.043733587   Up
  CYP4F3    0.707298362        0.025967428   4.648357447   8.950444777   Up
  CXCL8     0.651965182        0.048148598   6.882829746   11.04384805   Up
  CLEC4D    0.636486225        0.047074356   2.579585737   3.692774365   Up
  FAM118A   0.634156346        0.010715671   0.992441488   2.574184644   Up

DEmRNAs, differentially expressed mRNAs; fpkm, fragments per kilobase million; C, control group; T, case group.

###### 

Top 10 up- and downregulated DElncRNAs between the patients with ankylosing spondylitis and the normal controls.

  DElncRNAs       log2.Fold change   P*-*value     SD_fpkm_C     SD_fpkm_T     Regulation
  --------------- ------------------ ------------- ------------- ------------- ------------
  MSTRG.9221      −2.900321700       0.018550654   4.278074312   0.276811741   Down
  MSTRG.1368      −2.619486415       0.003067593   1.673345961   0             Down
  AL928768.3      −2.320417178       0.018613919   1.432426837   0.766958784   Down
  WDR86-AS1       −1.749482818       0.045879379   5.820719606   0.430167793   Down
  GS1-393G12.12   −1.595574045       0.025413087   2.892968281   0.573066828   Down
  RP11-75C10.7    −1.578454562       0.028918409   1.681378986   0.27755832    Down
  MSTRG.22984     −1.515487489       0.028151217   6.307372767   6.856887292   Down
  RP1-29C18.8     −1.491219357       0.007182308   1.813751882   0.780203396   Down
  RP11-20I20.4    −1.489870084       0.045895116   1.882568915   0.702213888   Down
  CTD-2531D15.5   −1.452569255       0.044459184   1.198212257   0             Down
  AC010084.1      1.812545185        0.005654266   0             0.808113485   Up
  PSMD5-AS1       1.788651473        0.011076928   8.927660428   20.42027077   Up
  RP11-535M15.1   1.639437785        0.00820557    0             1.477784502   Up
  LLPH-AS1        1.498657545        0.005471274   0.230318651   2.298519226   Up
  RP4-811H24.9    1.452389476        0.004968106   0.053490925   0.499762058   Up
  MSTRG.30231     1.342076952        0.040559246   2.874551067   6.364192991   Up
  TMEM92-AS1      1.339293051        0.014889801   0             1.352052251   Up
  WI2-87327B8.2   1.289651543        0.017494757   1.241932483   1.714464098   Up
  AC099668.5      1.25464443         0.023121561   0             1.059053016   Up
  LINC01151       1.231390756        0.00790838    0.384761558   0.385097694   Up

DElncRNA, differentially expressed long non-coding RNA; fpkm, fragments per kilobase million; C, control group; T, case group.

###### 

The top 100 co-expressed differentially expressed mRNA-differentially expressed long non-coding RNA interaction network.

  mRNAsig         lncRNAsig       corsig         pvalsig
  --------------- --------------- -------------- --------------
  OR5B2           RP11-524O1.4    0.999999784    7.02×10^−14^
  ADAMTS14        RP5-906A24.2    0.999998855    1.97×10^−12^
  ADAMTS14        KCNMB2-AS1      0.99999619     2.18×10^−11^
  DMRTC2          RP11-756H6.1    0.9999959      2.52×10^−11^
  PRY             RP11-355N15.3   0.999995538    2.99×10^−11^
  CAMSAP3         LINC01337       0.999993952    5.49×10^−11^
  GPR62           LINC01337       0.999993931    5.52×10^−11^
  ACTN3           AC004471.9      0.999985033    3.36×10^−10^
  COL21A1         LINC01337       0.999984742    3.49×10^−10^
  OR5B2           RP11-91I20.2    0.9999843      3.70×10^−10^
  SFTA2           AC004471.9      0.999975676    8.88×10^−10^
  ADAMTS14        TSPEAR-AS1      0.999948189    4.03×10^−9^
  DMRTC2          TSPEAR-AS1      0.999936548    6.04×10^−9^
  FOXI1           RP5-906A24.2    0.999888814    1.85×10^−8^
  FOXI1           AC022431.3      0.999855298    3.14×10^−8^
  ERICH6          RP1-72A23.4     0.999853976    3.20×10^−8^
  DMRTC2          KCNMB2-AS1      0.99982545     4.57×10^−8^
  FOXI1           KCNMB2-AS1      0.999815958    5.08×10^−8^
  OR2C3           RP11-355N15.3   0.999806865    5.59×10^−8^
  FOXI1           RP11-320N21.1   0.999759427    8.68×10^−8^
  PAK6            PSMD5-AS1       0.999743004    9.91×10^−8^
  DMRTC2          RP5-906A24.2    0.999736476    1.04×10^−7^
  CAMSAP3         RP11-254I22.2   0.999726506    1.12×10^−7^
  GPR62           RP11-254I22.2   0.99972637     1.12×10^−7^
  SFTA2           RP11-320N21.1   0.99970509     1.30×10^−7^
  ADAMTS14        RP11-756H6.1    0.999704563    1.31×10^−7^
  ERICH6          RP11-254I22.2   0.999685951    1.48×10^−7^
  COL21A1         RP11-254I22.2   0.999676565    1.57×10^−7^
  OR2C3           RP11-524O1.4    0.999662773    1.71×10^−7^
  FOXI1           TSPEAR-AS1      0.999646107    1.88×10^−7^
  SFTA2           AC022431.3      0.999573412    2.73×10^−7^
  PRY             RP11-203E8.1    0.999549564    3.04×10^−7^
  PRY             RP11-104N10.1   0.999534887    3.24×10^−7^
  OR2C3           RP11-91I20.2    0.999522111    3.43×10^−7^
  PRY             RP4-736L20.3    0.999509557    3.61×10^−7^
  FCRL4           CTD-2534I21.8   0.999489932    3.90×10^−7^
  ADAMTS14        AC022431.3      0.999441016    4.69×10^−7^
  PRY             AC008781.7      0.999421699    5.02×10^−7^
  ACTN3           RP11-320N21.1   0.999325423    6.82×10^−7^
  FZD9            AC008781.7      0.999315145    7.03×10^−7^
  RP11-505K9.4    RP11-756H6.1    0.999273631    7.91×10^−7^
  ADAMTS14        RP11-320N21.1   0.999264308    8.12×10^−7^
  FZD9            RP4-736L20.3    0.999211985    9.31×10^−7^
  FZD9            RP11-104N10.1   0.99917912     1.01×10^−6^
  FOXI1           RP11-756H6.1    0.999170485    1.03×10^−6^
  FZD9            RP11-203E8.1    0.99915935     1.06×10^−6^
  PDZD4           RP11-159N11.4   0.999141006    1.11×10^−6^
  ACTN3           AC022431.3      0.999132502    1.13×10^−6^
  RP11-219A15.1   RP11-457M11.7   0.999106184    1.20×10^−6^
  CAMSAP3         RP1-72A23.4     0.999004264    1.49×10^−6^
  GPR62           RP1-72A23.4     0.999004022    1.49×10^−6^
  OR5B2           RP11-355N15.3   0.998989141    1.53×10^−6^
  ERICH6          LINC01337       0.998988895    1.53×10^−6^
  CXXC5           LINC01588       0.998981114    1.56×10^−6^
  FZD9            RP1-72A23.4     0.998951532    1.65×10^−6^
  COL21A1         RP1-72A23.4     0.99891675     1.76×10^−6^
  NDUFC2-KCTD14   RP11-45A17.2    -0.998877807   1.89×10^−6^
  MAP4            MSTRG.8559      0.998862021    1.94×10^−6^
  PRY             RP11-524O1.4    0.998818651    2.09×10^−6^
  SRGN            CTD-2562G15.3   0.998661182    2.69×10^−6^
  RP11-505K9.4    TSPEAR-AS1      0.998635484    2.79×10^−6^
  OR2C3           RP11-203E8.1    0.998613936    2.88×10^−6^
  OR2C3           RP11-104N10.1   0.998588286    2.99×10^−6^
  FOXI1           AC004471.9      0.998585363    3.00×10^−6^
  PRY             RP11-91I20.2    0.998566098    3.08×10^−6^
  ZNF804A         TCEAL3-AS1      0.99856452     3.09×10^−6^
  FAM111A         MSTRG.6714      0.998552192    3.14×10^−6^
  OR2C3           RP4-736L20.3    0.998544416    3.18×10^−6^
  DMRTC2          AC022431.3      0.998494339    3.40×10^−6^
  OR2C3           AC008781.7      0.99839571     3.86×10^−6^
  HHAT            AC012074.2      0.998323875    4.21×10^−6^
  IL18BP          MSTRG.8559      0.998273402    4.47×10^−6^
  RP5-862P8.2     RP11-1H8.5      0.998269298    4.49×10^−6^
  SMAD6           RP5-1092A3.5    0.998257122    4.55×10^−6^
  CFAP20          MSTRG.8559      0.998252424    4.58×10^−6^
  RP11-505K9.4    KCNMB2-AS1      0.998220553    4.75×10^−6^
  DMRTC2          RP11-320N21.1   0.998212166    4.79×10^−6^
  PCOLCE2         RP11-105C19.2   -0.998176846   4.98×10^−6^
  SFTA2           RP5-906A24.2    0.998131862    5.23×10^−6^
  FZD9            RP11-254I22.2   0.998116114    5.32×10^−6^
  ARL11           DNAJC3-AS1      0.998052713    5.68×10^−6^
  MYOF            LINC01151       -0.998035735   5.78×10^−6^
  NT5C2           RP11-139H15.6   0.998022562    5.86×10^−6^
  MME             RP11-295I5.4    0.998001494    5.99×10^−6^
  RP11-505K9.4    RP5-906A24.2    0.99795661     6.26×10^−6^
  IL18BP          MYCBP2-AS2      0.997935664    6.39×10^−6^
  HSPA1L          LINC01588       0.997924492    6.46×10^−6^
  SAMHD1          MYCBP2-AS2      0.997902735    6.59×10^−6^
  SFTA2           KCNMB2-AS1      0.997861652    6.85×10^−6^
  CSNK2B          RP11-214K3.23   0.997833473    7.04×10^−6^
  NOLC1           MSTRG.8559      0.997817608    7.14×10^−6^
  TNXB            RP11-441F2.2    0.997791211    7.31×10^−6^
  RHOB            LINC00671       0.997708778    7.87×10^−6^
  DDB1            RP11-429J17.2   0.997652855    8.26×10^−6^
  ORMDL3          MYCBP2-AS2      0.997626959    8.44×10^−6^
  OR5B2           RP11-927P21.2   0.99758326     8.75×10^−6^
  ADAMTS14        AC004471.9      0.997577319    8.80×10^−6^
  TRIM73          RP11-565F19.2   0.997494288    9.41×10^−6^
  PEG3            RP11-17E13.2    0.997467797    9.61×10^−6^

lncRNA, long non-coding RNA.

###### 

Nearby targeted DEmRNAs of DElncRNAs between ankylosing spondylitis and normal controls.

  Chr       DElncRNA            Nearby DEmRNA                                            
  --------- ------------------- --------------- ------------- ------------ ------------- -------------
  chr1      PIK3CD-AS1          9,552,610       9,754,586     CLSTN1       9,729,026     9824526
  chr14     LINC01588           49,827,571      50,192,643    SOS2         50,117,120    50,231,558
  chr22     AC004471.9          19,021,529      19,224,503    SLC25A1      19,175,575    19,178,830
  chr2      AC007879.5          207,139,864     207,629,795   KLF7         207,074,137   207,167,267
  ChrX      INE1                47,104,921      47,305,865    UBA1         47,190,861    472,151,28
  ChrX      INE1                47,104,921      47,305,865    USP11        47,232,690    47,248,328
  chr1      TAF1A-AS1           222,489,825     222,693,032   MIA3         222,618,086   222,668,012
  chr7      AC007285.6          29,888,600      30,125,660    SCRN1        29,920,103    29,990,289
  chr1      RP11-318C24.2       175,804,762     176,020,513   RFWD2        175,944,831   176,207,493
  chr5      AC008781.7          141,518,414     141,726,481   DIAPH1       141,515,016   141,619,055
  chr3      U73166.2            50,160,303      50,363,358    HYAL3        50,292,831    50,299,468
  ChrX      RP13-314C10.5       23,672,992      23,882,956    PRDX4        23,664,262    23,686,399
  chr1      RP11-195C7.1        176,107,648     176,329,330   RFWD2        175,944,831   176,207,493
  chr21     AP001056.1          44,075,489      44,276,453    PWP2         44,107,290    44,131,181
  chr21     AP001056.1          44,075,489      44,276,453    TRAPPC10     44,012,319    44,106,552
  chr1      RP11-7O11.3         43,844,370      44,046,551    ST3GAL3      43,705,824    43,931,165
  chr3      RP11-379K17.4       169,839,353     170,066,734   GPR160       170,037,929   170,085,403
  chr2      AC092620.2          138469090       138,674,458   SPOPL        138,501,801   138,573,547
  chr3      LINC00969           195,558,062     195,839,964   MUC20        195,720,882   195,741,123
  chr4      RP11-15B17.1        99,850,006      100,295,099   LAMTOR3      99,878,336    99,894,490
  chr5      SCAMP1-AS1          78,242,365      78,460,507    AP3B1        78,000,525    78,294,755
  chr15     RP11-30K9.6         58,668,072      58,870,974    ADAM10       58,588,807    58,749,978
  chr8      BAALC-AS1           103,056,990     103,398,772   SLC25A32     103,39,8635   103,415,189
  chr5      RP11-159F24.5       43,415,274      43,625,310    NNT          43,602,692    43,707,405
  chr5      LINC01187           170,091,579     170,299,141   FOXI1        17,010,5897   170,109,725
  chr8      LINC01151           122,570,385     122,794,106   ZHX2         122,781,394   122,974,512
  chr11     RP11-727A23.4       83,080,144      83,284,520    PCF11        83,156,988    83,187,451
  chr8      GS1-393G12.12       144,214,590     144,415,138   BOP1         144,262,102   144,291,370
  chr12     RP11-561P12.5       8,448,361       8,667,613     CLEC4E       8,533,305     8,540,963
  chr12     RP11-561P12.5       8,448,361       8,667,613     CLEC4D       8,509,475     8,522,366
  chr12     RP11-996F15.2       29,180,418      29,417,848    ERGIC2       29,337,352    29,381,189
  chr14     RP11-44N21.1        104,993,609     105,199,004   CDCA4        105,009,573   105,021,148
  chr14     RP11-44N21.1        104,993,609     105,199,004   C14 or f79   104,985,775   105,010,482
  chr12     RP11-753H16.3       54,253,661      54,597,688    HNRNPA1      54,280,193    54,287,088
  chr14     RP11-193F5.1        60,779,714      61,082,585    SLC38A6      60,981,114    61,083,733
  chr14     RP5-1021I20.1       73,687,360      73,903,270    PNMA1        73,711,783    73,714,372
  chr3      AC099668.5          49,584,480      49,784,983    MST1         49,683,947    49,689,501
  chr6      RP11-425D10.10      109,282,795     109,483,666   SMPD2        109,440,763   109,443,919
  chr14 C   TD-2547L24.4        91,158,299      91,359,003    CCDC88C      91,271,323    91,417,844
  chr14     RP11-524O1.4        21,284,292      21,484,920    CHD8         21,385,194    21,456,126
  chr14     RP11-524O1.4        21,284,292      21,484,920    SUPT16H      21,351,472    21,384,266
  chr16     RP11-459F6.3        58,029,529      58,259,133    CFAP20       58,113,588    58,129,450
  chr16     RP11-264B17.3       28,874,804      29,090,775    LAT          28,984,826    28,990,783
  chr1      RP11-196G18.22      149,744,498     149,949,024   HIST2H2BF    149,782,689   149,812,373
  chr16     LA16c-306E5.3       3,358,071       3,615,564     NLRC3        3,539,033     3,577,400
  chr16     RP11-461A8.4        3,550,636       3,751,703     NLRC3        3,539,033     3,577,400
  chr17     RP1-59D14.5         2,275,061       2,479,306     TSR1         2,322,503     2,337,507
  chr17     RP1-59D14.5         2,275,061       2,479,306     METTL16      2,405,562     2,511,891
  chr17     RP1-59D14.5         2,275,061       2,479,306     SMG6         2,059,839     2,303,771
  chr17     RP11-927P21.2       64,799,766      65,000,716    LRRC37A3     64,854,312    64,919,480
  chr17     RP11-1094M14.11     35,468,109      35,674,843    SLFN14       35,548,125    35,558,098
  chr17 C   TD-2534I21.8        44,847,912      45,048,939    EFTUD2       44,849,943    44,899,662
  chr19     PTOV1-AS1           49,738,639      49,951,676    NUP62        49,906,825    49,929,763
  chr20     RP4-591C20.9        63,761,212      63,964,293    UCKL1        63,939,829    63,956,415
  chr19     AC007292.3          4,256,637       4,458,448     CCDC94       4,247,079     4,269,090
  chr19     RAB11B-AS1          8,274,373       8,490,685     RAB11B       8,389,981     8,404,434
  chr5      CTD-2033C11.1       65,824,629      66,025,135    ERBIN        65,926,475    66,082,549
  chr4      RP11-572O17.1       1,612,821       1,813,622     FAM53A       1,617,915     1,684,302
  chr4      RP11-572O17.1       1,612,821       1,813,622     LETM1        1,811,479     1,856,247
  chr1      RP4-736L20.3        10,329,881      10,530,677    DFFA         10,456,522    10,472,526
  chr10     RP11-574K11.29      73,603,735      73,813,581    USP54        73,497,538    73,625,953
  chr1      RP11-156E8.1        244,869,350     245,071,088   EFCAB2       244,969,705   245,127,164
  chr3      RP11-767C1.2        12,732,219      12,932,728    IQSEC1       12,897,220    13,073,117
  chr1      RP11-11N7.4         244,764,738     244,965,272   HNRNPU       244,840,638   244,864,560
  chr3      RP11-778D9.13       184,032,942     184,233,561   AP2M1        184,174,689   184,184,091
  chr12     RP1-197B17.4        47,631,908      47,832,351    HDAC7        47,782,722    47,833,132
  chr17     AC142472.6          45,046,730      45,248,470    NMT1         45,051,610    45,109,016
  chr15 C   TD-2562G15.3        75,352,964      75,553,947    SIN3A        75,369,379    75,455,842
  chr17     RP11-333J10.3       36,898,598      37,100,034    AATF         36,948,875    37,056,871
  chr15 C   TD-2382E5.6         41,808,204      42,008,714    JMJD7        41,828,085    41,837,581
  chr18     RP11-405M12.3       74,970,197      75,171,091    ZNF407       74,597,870    75,065,671
  chr17     HEXDC-IT1           82,325,498      82,527,310    NARF         82,458,180    82,490,537
  chr17     RP11-159D12.6       57,906,674      58,108,187    CUEDC1       57,861,243    57,955,323
  chr15     RP11-1H8.5          34315,450       34,520,273    LPCAT4       34,358,618    34,367,278
  chr15     RP11-1H8.5          34,315,450      34,520,273    SLC12A6      34,229,996    34,338,060
  chr5      CTC-487M23.6        112,794,933     112,996,531   SRP19        112,861,222   112,869,788
  chr5      CTC-487M23.6        112,794,933     112,996,531   DCP2         112,976,702   113,020,970
  chr5      AC005593.2          131,697,415     131,897,929   FNIP1        131,641,714   131,797,063
  chr17     RP13-638C3.5        82,548,849      82,750,657    FN3KRP       82,716,683    82,730,328
  chr14     RP11-298I3.6        22,923,083      23,124,217    AJUBA        22,971,174    22,982,642
  chr16     RP11-451N19.3       58,605,799      58,806,297    SLC38A7      58,665,109    58,685,104
  chr16     RP11-451N19.3       58,605,799      58,806,297    GOT2         58,707,131    58,734,357
  chr19     CTD-2233K9.1        46,846,535      47,049,156    ARHGAP35     46,918,676    47,005,077
  chr6      XXbac-BPG283O16.9   30,182,349      30,386,054    RPP21        30,345,131    30,346,884
  chr6      XXbac-BPG283O16.9   30,182,349      30,386,054    TRIM26       30,184,455    30,213,427

Chr, chromosome; DEmRNAs, differentially expressed mRNAs; DElncRNA, differentially expressed long non-coding RNA.
